GlaxoSmithKline's shares rose Thursday after the healthcare company announced US approval of Breo Ellipta, a treatment for chronic obstructive pulmonary disease (COPD).
Breo Ellipta, once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with COPD, was given the green light from the Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee.
The committee voted that the efficacy and safety data provide substantial evidence to support approval of the medication. The company submitted a new drug application to the FDA for approval of Breo last July.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
"We are pleased with the outcome of today's meeting," said President of GlaxoSmithKline Pharmaceuticals, Patrick Vallance.
"COPD is a debilitating and progressive disease. Its symptoms are often severe and can have a huge impact on patients' lives. This positive recommendation is a crucial first step towards making Breo Ellipta available for appropriate COPD patients across the US.
"We look forward to a final decision from the FDA later this year."
In the doghouse: hundreds of investment funds are underperforming - is it time to sell?
News The latest Spot The Dog research from Bestinvest reveals 151 funds are failing to beat their benchmark. We reveal the worst performers
By Marc Shoffman Published
Nationwide: House prices creep up for the first time in over a year
Nationwide’s latest house price index reveals property prices are finally rising. Will this pattern continue in 2024?
By Vaishali Varu Published